Zhi-Yong Wu

发表

Neoadjuvant docetaxel plus carboplatin vs epirubicin plus cyclophosphamide followed by docetaxel in triple‐negative, early‐stage breast cancer (NeoCART): Results from a multicenter, randomized controlled, open‐label phase II trial

Jieqing Li, Ying Lin, Kun Wang, 2021, International journal of cancer.

Markers Associated With Tumor Recurrence in Patients With Breast Cancer Achieving a Pathologic Complete Response After Neoadjuvant Chemotherapy

Zhongyu Yuan, Si-qi Qiu, Haiquan Chen, 2022, Frontiers in Oncology.

Neoadjuvant docetaxel plus carboplatin vs epirubicin plus cyclophosphamide followed by docetaxel in triple‐negative, early‐stage breast cancer (NeoCART): Results from a multicenter, randomized controlled, open‐label phase II trial

Jieqing Li, Ying Lin, Kun Wang, 2021, International journal of cancer.

Neoadjuvant TCH (docetaxel/darboplatin/trastuzumab) versus EC-TH (epirubicin/cyclophosphamide followed by docetaxel/ trastuzumab ) in patients with HER2-positive breast cancer (neoCARH): A randomised, open-label, multicenter, phase II trial.

Jieqing Li, Ying Lin, Kun Wang, 2020 .

Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment for Patients with Hormone Receptor–Positive and HER2-Positive Metastatic Breast Cancer (SYSUCC-002)

Ying Lin, X. An, Zhongyu Yuan, 2021, Clinical cancer research : an official journal of the American Association for Cancer Research.

DAGM: A novel modelling framework to assess the risk of HER2-negative breast cancer based on germline rare coding mutations

You-Qiang Song, Xiaoling Li, Jieqing Li, 2021, medRxiv.

Rare non-synonymous germline mutations systematically define the risk of triple negative breast cancer

You-Qiang Song, Xiaoling Li, Chunming Zhang, 2019 .

Impact of Homologous Recombination Deficiency on Outcomes in Patients With Triple-Negative Breast Cancer Treated With Carboplatin-Based Neoadjuvant Chemotherapy: Secondary Analysis of the NeoCART Randomized Clinical Trial.

Ying Lin, Kun Wang, Zhenzhen Liu, 2023, JCO precision oncology.

The efficacy of human epidermal growth factor receptor 2 (HER2) blockade switching mode in refractory patients with HER2-positive metastatic breast cancer: a phase II, multicenter, single-arm study (SYSUCC-005)

Ying Lin, Zhongyu Yuan, Le-hong Zhang, 2022, BMC Cancer.

Trastuzumab plus endocrine therapy or chemotherapy as first-line treatment for metastatic breast cancer with hormone receptor-positive and HER2-positive: The sysucc-002 randomized clinical trial.

Ying Lin, X. An, Zhongyu Yuan, 2021 .

Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment for Patients with Hormone Receptor–Positive and HER2-Positive Metastatic Breast Cancer (SYSUCC-002)

Ying Lin, X. An, Zhongyu Yuan, 2021, Clinical Cancer Research.

Longitudinal MRI-based fusion novel model predicts pathological complete response in breast cancer treated with neoadjuvant chemotherapy: a multicenter, retrospective study

Ying Lin, Kun Wang, T. Zhu, 2023, EClinicalMedicine.

Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment 1 for Patients with Metastatic Breast Cancer with Hormone Receptor-positive and 2 HER2-positive (SYSUCC-002)

Ying Lin, X. An, Zhongyu Yuan, 2021 .

Anthracycline-containing versus carboplatin-containing neoadjuvant chemotherapy in combination with trastuzumab for HER2-positive breast cancer: the neoCARH phase II randomized clinical trial

Jieqing Li, Ying Lin, Kun Wang, 2021, Therapeutic advances in medical oncology.

A non-invasive artificial intelligence model for identifying axillary pathological complete response to neoadjuvant chemotherapy in breast cancer: a secondary analysis to multicenter clinical trial.

T. Zhu, Zhi-Yong Wu, Kun Wang, 2024, British journal of cancer.

Multifactor artificial intelligence model assists axillary lymph node surgery in breast cancer after neoadjuvant chemotherapy: multicenter retrospective cohort study

T. Zhu, M. Cheng, Zhi-Yong Wu, 2023, International journal of surgery.